An American company has asked Oxfordshire researchers to help it in its quest for anti-ageing drugs.
Elixir Pharmaceuticals, of Massachusetts, which develops pharmaceuticals that slow aging and delay the onset of age-related diseases, has announced a three-year agreement with Evotec OAI, which employs more than 300 people at Milton Park, near Abingdon.
Evotec OAI, formed from the merger of an Oxford University spin-off company and a German biotech group, will search its library of 280,000 chemicals to find compounds which could become anti-ageing drugs.
Elixir chief executive Ed Cannon said: "Elixir's approach to creating long-term value is to focus our internal resources on understanding the biology and genetics of ageing and disease."
Elixir will use Evotec OAI's medicinal chemistry skills to design drugs.
Evotec chief executive Joern Aldag said: "Elixir's foundation of expertise in the biology and genetics of ageing leaves them ideally positioned to capitalise on the breadth of Evotec OAI's established chemistry and biology processes."
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article